Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWORD-2: Switching to Dolutegravir + Rilpivirine in Virologically Suppressed HIV-1
NCT02422797Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of dolutegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Apr 2015; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02422797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422797.